Keeping Track Of Withdrawals: Libtayo, Parsaclisib Applications Pulled Due To Postmarketing Issues

Changing therapeutic landscape may have complicated regulatory plans for Regeneron/Sanofi’s PD-1 inhibitor in second-line cervical cancer, while accelerated approval confirmatory trial timeline appears to have been an issue for Incyte’s PI3-kinase inhibitor in lymphoma.

Ship reversing course
Like a ship at sea, cancer drug sponsors are reversing course on applications under FDA review. • Source: Alamy

Postmarketing study issues were cited as the reason for two recent high-profile withdrawals of cancer drug applications under US Food and Drug Administration review.

For Regeneron Pharmaceuticals, Inc. and Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc), the regulatory path to a supplemental approval for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers